MIG - Press Review

 

2020

Alternativer Text

Handelsblatt -

Biotech-Firm Immatics from Tübingen with Nasdaq Listing

„Handelsblatt.com“ reports about the Listing of MIG-portfolio company Immatics at New Yorks Nasdaq.
Find out more
Alternativer Text

FOCUS -

Biontech Vaccine: Good data creat hope in turnaround

„Focus“ and other media report about good results of BioNTech, a MIG portfolio company, in search of a vaccine against Covid-19.
Find out more
Alternativer Text

Manager Magazin -

Singapurs Funds Temasek invests in BioNTech

„Manager Magazin“ reports about a 250 million investment of Temasek in BioNTech, a MIG portfolio company.
Find out more
Alternativer Text

FAZ -

„It´s not a question to participate in a race“

„Süddeutschen Zeitung“ interviews Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, about the state of the art in developing a vaccine against Covid-19.
Find out more
Alternativer Text

FOCUS, Heft 23/2020 -

The next quantum leap

In an article in detail „Focus“ describes the state of the art of quantum computing in Europe and mentions MIG portfolio company IQM as a main player.
Alternativer Text

Focus -

Costs nothing, not destroyable

Magazine „Focus“ reports, how Airbus will beat Boing with new materials from Amsilk, a MIG-portfolio company.
Find out more
Alternativer Text

EU-Startups -

10 promising European deeptech startups leading us into the future

Platform „EU-Startups“ provides an overview of European „deeptech startups“ and highlights MIG-portfolio company IQM and the founder Dr. Jan Goetz.
Find out more
Alternativer Text

Manager Magazin -

Biontech expects first data til July in their development of a vaccine against Covid-19

Several media reports new steps of BioNTech, a MIG portfolio company, in search of a vaccine against the new Coronavirus.
Find out more
Alternativer Text

Gründerszene -

The start-up of this German build hardware for Quantumcomputers

„Gründerszene“ portrays Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.
Find out more
Alternativer Text

Tagesschau, FAZ and other media -

First clinical study for a Corona-Vaccine in Germany approved

FAZ and other media report, that in Germany for the first time a clinical study got the approval to test a Corona-Vaccine. MIG-Portfolio company BioNTech is allowed to start tests of his vaccine with volunteers.
Find out more
Find out more
Alternativer Text

Handelsblatt -

Biontech and Pfizer are planning to produce millions of units of Corona-vaccine this year

Handelsblatt.com reports about the plans of BioNTech, a portfolio company of MIG Fonds, to develop and produce a vaccine against Covid-19 together with Pfizer.
Find out more
Alternativer Text

Manager Magazin -

Power-Paar against SARS-CoV-2

„Manager Magazin Online“ portrays Ugur Sahin and Özlem Türeci of BioNTech and acknowledge the role of MIG Fonds in founding and financing the firm.
Find out more
Alternativer Text

DIE ZEIT -

Saving the World

Weekly Magazine „DIE ZEIT“ reports about pharmaceutical companies searching for vaccines against SARS CoV-2 focusing on BioNTech, a MIG portfolio company.
Find out more
Alternativer Text

Going Public Media -

AFFiRiS erhält Patent für Parkinson-Medikament in China

„Going Public“ reports about progresses of MIG portfolio company AFFiRiS. The biotech firm, based in Vienna, got a patent in China and will start a clinical study (Parkinson) in the second half of the year.
Find out more
Alternativer Text

Financial Times -

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.
Find out more
Alternativer Text

transkript, Finanzwelt und andere -

Immatics is planning a listing on the Nasdaq

Several national and international media are reporting about the IPO-plans of MIG portfolio company Immatics in Q2. on the Nasdaq.
Find out more
Find out more
Find out more
Alternativer Text

Reuters, Handelsblatt, FAZ -

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.
Find out more
Find out more
Find out more
Alternativer Text

Life Science -

The IPO took BioNTech onto the international stage

„Life Sciences“ is interviewing Sierk Pötting, BioNTech SE, and Michael Motschmann, General Partner der MIG AG, about the success of BioNTech.
Mehr erfahren
Alternativer Text

Reuters -

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.
Find out more
Alternativer Text

Finanzwelt -

Third Investment of MIG 16

Trade magazine „Finanzwelt“ reports about MIG Fonds newest investment in Neracare GmbH.
Find out more
Alternativer Text

OLED Brief -

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.
Find out more
Alternativer Text

transkript -

Immatics closes second TCR-T-Billion Deal

Trade Magazine „transkript“ reports about a deal between immatics, a MIG porfolio company, and GlaxoSmithKline, which assures immatics milestone payments up to 1.1 Billion US Dollar.
Find out more
Alternativer Text

Finanzwelt -

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.
Find out more
Alternativer Text

Gründerszene -

„For me it would not be enough to sell shoes online“

Interview with Gloria Seibert, founder of Temedica, a new MIG portfolio company.
Find out more
Alternativer Text

transkript -

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.
Find out more
Alternativer Text

Wirtschaftswoche, Munich Start-up, Going Public Media, kma, Gründerszene -

Series B Funding of Temedica

Several media report about the 17 million Euro series-B-financing round of Temedica, which was led by MIG Fonds.
Find out more
Find out more
Find out more